2018 Enterocolitis Drug Development- Pipeline Analysis Report
Necrotizing enterocolitis (NEC) is a devastating inflammatory bowel disease which can completely damage the intestine walls, causing holes in the intestine and leak out of stool into abdomen. The highly infectious disease occurs predominantly in premature infants. An estimated 10,000 births are affected in the US.
Around 10 companies and universities are focusing on developing treatment options for Enterocolitis.
To assist investigators and funding and regulatory organizations, VPA Research has come up with a comprehensive report on Enterocolitis pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Enterocolitis pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Enterocolitis pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
Around 10 companies and universities are focusing on developing treatment options for Enterocolitis.
To assist investigators and funding and regulatory organizations, VPA Research has come up with a comprehensive report on Enterocolitis pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Enterocolitis pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Enterocolitis pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
1 TABLE OF CONTENTS
1.1 List of Figures
1.2 List of Tables
2 ENTEROCOLITIS PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Enterocolitis Pipeline Snapshot
2.3 Enterocolitis Pipeline by Phase
2.4 Enterocolitis Pipeline by Company
2.5 Enterocolitis Pipeline by Mechanism of Action
3 ENTEROCOLITIS- COMPANY WISE PIPELINE ANALYSIS
Avexegen Therapeutics
Glycosyn LLC
Infant Bacterial Therapeutics
Leadiant Biosciences
ProMetic Life Sciences
4 ENTEROCOLITIS R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN ENTEROCOLITIS PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
1.1 List of Figures
1.2 List of Tables
2 ENTEROCOLITIS PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Enterocolitis Pipeline Snapshot
2.3 Enterocolitis Pipeline by Phase
2.4 Enterocolitis Pipeline by Company
2.5 Enterocolitis Pipeline by Mechanism of Action
3 ENTEROCOLITIS- COMPANY WISE PIPELINE ANALYSIS
Avexegen Therapeutics
Glycosyn LLC
Infant Bacterial Therapeutics
Leadiant Biosciences
ProMetic Life Sciences
4 ENTEROCOLITIS R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN ENTEROCOLITIS PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
LIST OF FIGURES
Figure 1: Enterocolitis Pipeline by Phase, H1- 2018
Figure 2: Enterocolitis Pipeline by Companies, H1- 2018
Figure 3: Company Wise Pipeline Drug Phases, H1- 2018
Figure 4: Enterocolitis Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H1- 2018
Figure 1: Enterocolitis Pipeline by Phase, H1- 2018
Figure 2: Enterocolitis Pipeline by Companies, H1- 2018
Figure 3: Company Wise Pipeline Drug Phases, H1- 2018
Figure 4: Enterocolitis Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H1- 2018
LIST OF TABLES
Table 1: Enterocolitis Pipeline by Phase, H1- 2018
Table 2: Enterocolitis Pipeline by Companies, H1- 2018
Table 3: Enterocolitis Pipeline by Mechanism of Action, H1- 2018
Table 4: Avexegen Therapeutics Enterocolitis Pipeline, May 2018
Table 5: Glycosyn LLC Enterocolitis Pipeline, May 2018
Table 6: Infant Bacterial Therapeutics Enterocolitis Pipeline, May 2018
Table 7: Leadiant Biosciences Enterocolitis Pipeline, May 2018
Table 8: ProMetic Life Sciences Enterocolitis Pipeline, May 2018
Table 1: Enterocolitis Pipeline by Phase, H1- 2018
Table 2: Enterocolitis Pipeline by Companies, H1- 2018
Table 3: Enterocolitis Pipeline by Mechanism of Action, H1- 2018
Table 4: Avexegen Therapeutics Enterocolitis Pipeline, May 2018
Table 5: Glycosyn LLC Enterocolitis Pipeline, May 2018
Table 6: Infant Bacterial Therapeutics Enterocolitis Pipeline, May 2018
Table 7: Leadiant Biosciences Enterocolitis Pipeline, May 2018
Table 8: ProMetic Life Sciences Enterocolitis Pipeline, May 2018
